Michael P Czech

UMassMed Faculty Page

Inventions:

Title: Selective, siRNA-Mediated Knockdown of CB1 Receptors in Macrophages for the Treatment of Diabetes. UMMS13-52; Patent Pending.

• Novel compositions and methods for the treatment of type 2 diabetes mellitus using glucan-encapsulated siRNA directed against human cannabinoid receptor 1 (CB1). The glucagon-encapsulated siRNA's specifically target phagocytic macrophages upon administration.

  • Technology: RNAi/micro-RNA Therapy
  • Applications: Type II Diabetes, Metabolic endocannabinoids

Title: Peptide-modified Glucagon Particles for Delivery of Therapeutic Cargoes. UMMS13-05; Patent Pending. 

• This technology embodies a novel delivery vehicle for RNAi, particularly amenable to therapeutic targeting of gut inflammatory cytokines via oral administration. The invention discloses amine conjugated glucan particles, extracted from yeast cell walls, for the delivery of nucleic acid cargoes. 

  • Technology: Gene Therapy, RNAi/micro-RNA Therapy
    
  • Applications: Inflammatory bowel disease, Irritable bowel syndrome, Gene therapy improvement

Title: COMPOSITIONSANDMETHODSFOR DECREASING LEUKOCYTE EXTRAVASATION AND VESSEL FLUID LEAKAGE. UMMS12-52; 9,434,951. 

• The technology provides novels compositions and methods for preventing formation of atherosclerotic plaques by administering inhibitory oligonucleotides, e.g. miRNA, that decrease Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4).  This invention is based on the discovery that oligonucleotides that decrease the expression of Map4k4 mRNA in an endothelial cell reduce the induction of leukocyte adhesion molecules and reduce endothelial cell monolayer permeability.  Further provided are methods of using oligonucleotides targeting Map4k4 therapeutic agents for atherosclerosis.

  • Technology: RNAi/micro-RNA Therapy
  • Applications: Atherosclerosis, Cardiovascular disease/Cardiology
  • Patent Expiration Dates: Active

Title: COMPOSITIONS AND METHODS FOR INDUCING MYOBLAST DIFFERENTIATION AND MYOTUBE FORMATION. UMMS12-29; Patent 9,506,033. 

• The technology provides novels compositions and methods for treating muscle disorders comprising administration of inhibitory oligonucleotides and ribozymes that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) in myoblasts or myocytes. Futher provided are methods of using oligonucleotides targeting Map4k4 to induce differentiation of the myoblast to a mature myocyte that can be used as a research tool to identify therapeutic agents. 

• Technology: Research Tools 
• Applications: Muscle atrophy, Myopathy, Chronic fatigue syndrome, Fibromyalgia, Muscular dystrophy, Fatigue fibromyalgia, Spinal muscular atrophy, Duschenne Muscular Dystrophy (DMD), Claudication, Polymyalgia rheumatica, Rhabdomyolysis, Polymyositis

Title: ENCAPSULATED NANOPARTICLES FOR NUCLEIC ACID DELIVERY. UMMS08-09; Patent 8,389,485  

• This invention discloses a new method for delivery of nucleic acids, including agents for gene silencing (e.g. siRNAs). This new system is developed with exterior of yeast cell wall particle (YCWP) and interior comprising multilayer nanoparticle core with a payload complex. Using this technology, inventors have effectively shown siRNA can be delivered effectively in macrophages. 

• Technology: RNAi/micro-RNA Therapy 
• Applications: Drug delivery vehicle, Metabolic endocannabinoids, Metabolic inflammation, Type II Diabetes 
• Patent Expiration Dates: 2029-04-24 

 

Innovation Topics: RNAi/micro-RNA Therapy, Type II Diabetes, Metabolic endocannabinoids, Gene Therapy, Inflammatory bowel disease, Irritable bowel syndrome, Gene therapy improvement, Atherosclerosis, Cardiovascular disease/Cardiology, Research Tools, Muscle atrophy, Myopathy, Chronic fatigue syndrome, Fibromyalgia, Muscular dystrophy, Fatigue fibromyalgia, Spinal muscular atrophy, Duschenne Muscular Dystrophy (DMD), Claudication, Polymyalgia rheumatica, Rhabdomyolysis, Polymyositis, Drug delivery vehicle, Metabolic endocannabinoids, Metabolic inflammation